Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, has appointed Andrew Satlin, M.D., as executive vice president and chief medical officer.

Dr. Satlin has 20 years of industry experience in all phases of drug development across multiple areas, and most recently was at Eisai, where he spent nine years. He also has experience in the design and conduct of clinical trials in Alzheimer’s disease, Parkinson’s disease, epilepsy, schizophrenia, depression, anxiety, heart failure, and hypertension.

“We are excited to welcome Dr. Satlin as we continue to expand our team. Andy is a respected industry leader who strengthens our expertise in CNS drug development, and we look forward to working together as we continue the development of lumateperone and our pipeline,” said Dr. Sharon Mates, chairman and chief executive officer of Intra-Cellular Therapies.